Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease - Wikidata - wikimedia - TriplyDB

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

http://www.wikidata.org/entity/Q34286393

about

Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.Alzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States.Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer's Disease.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia.Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Amyloid pathology in the progression to mild cognitive impairment.Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.An Algorithm for Preclinical Diagnosis of Alzheimer's Disease.Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species

P2860

Q26770708-CA0AB490-B8B3-454E-96C0-C1FA918B48E6 Q26781635-DCAEA6BC-09C2-4E8B-A5A8-79AE5ACCAF4F Q28273817-739D2AAC-BA2E-4CBB-86BF-EBBFC9AEAA36 Q30996799-096A03E0-8D46-43E2-BFBE-2F3D402BD3E3 Q33604453-0164BA34-276D-4C3D-9849-0E9AA0ECD0DE Q34477459-24F72820-5219-460C-9035-CF88D573DF9D Q34493453-4DDAA093-7F7B-4302-BA33-2C4B85BC78E8 Q35119389-F5FF6AF8-D3BB-4485-8ADF-2CE851A344F3 Q35695716-52B2311B-BF0C-44EA-B673-82A47C8EDA49 Q35905536-A43833B3-ADD6-4703-A6BC-F70232B67500 Q36276592-4530AE63-8B1A-4591-988B-7EB3210DBD81 Q36554846-1D7DC61D-5164-482B-A18B-93FF550A317F Q37049024-5B14D2F3-A753-4BE0-8862-0F854B4A1BA2 Q38653401-A33D701B-5537-4D34-BB2D-312A37D4ABC6 Q38814839-288097A6-83FD-4EA6-B76A-FDFD6E9C4286 Q38825497-95D89E9B-4192-442F-903F-78D7953EF5A5 Q39029436-3AD95FC9-2EFD-4F2A-9117-DA7A584B2977 Q39309631-4A1916D6-8766-428D-ACBF-6E357BB1B44F Q39451605-F0A3D509-43AB-4417-8C66-3A3EFD6D004B Q39753296-4DD11C0F-332C-46F7-9EF4-D5F6EA914B1A Q41140682-D1696854-F6F6-466D-8C6C-54DE935A0FA2 Q42630406-79B02913-C347-43E6-B879-669DA62A629C Q47209544-79E982CA-BA0F-4FD2-8129-558C2144F07F Q47651177-2BAF01C0-DB8D-4979-B964-2BC91D6EBFF6 Q48468789-51DDDF33-D12A-475C-BEDC-2CA5E8F2DBAF Q52644601-F8C48B4B-062B-4446-BDA7-BB3D174AF2D4 Q52675910-21A71015-4386-43BE-8978-45D9509A7429 Q55146345-2C256BEC-3CC9-4DBC-A579-013B27997AB4 Q58696763-E9FB2CAC-7AF7-492E-B243-F106282674A6 Q58766037-1C292A6A-736E-4BA7-8812-6D18D998D433

P2860

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

http://www.wikidata.org/entity/Q34286393

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@ast

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@en

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@nl

type

label

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@ast

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@en

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@nl

prefLabel

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@ast

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@en

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@nl

P1433

Q34286393-FED05FF5-8418-417D-8108-0950FF11E5AD

P1476

Q34286393-518D95B4-E90D-446A-AE69-831973931B7C

P2093

Q34286393-0DCE55F7-CD65-4A86-998E-25F0A2973406

Q34286393-1C5B05E5-0718-45A7-BB32-90D4D2256F85

Q34286393-9442C1E5-A40E-4562-8E8C-E12B746F4C96

Q34286393-DA74E45D-6172-42D9-816A-D7E9FEB1D083

P2860

Q34286393-183D6EF7-218D-40D1-AC00-4BAEF6BA8D27

Q34286393-289E2974-D524-46F4-A2F6-4B9CA73D1ED2

Q34286393-2FB9BC9D-AA47-4A52-8024-E8FC0D6CE98A

Q34286393-36F259A8-A79D-422D-97AB-63D995B3E07E

Q34286393-4259583D-FC73-43AF-8B89-0A20750FE883

Q34286393-45D14EDE-F9AA-4B4D-BEB9-DF680B92B4C8

Q34286393-55CB613D-580A-48C4-80BD-EF0937D101E0

Q34286393-59FA02A4-24D4-40D0-BAA3-0E81ECA4C9F7

Q34286393-5D44A768-F965-4613-BD02-DF1F6DB3A6EF

Q34286393-5EB55907-B327-4042-B276-F1E8E07C390A

P304

Q34286393-0D7856F0-3C85-4C0A-965C-664B96223169

P31

Q34286393-5CC26D4D-27EC-4722-88DE-6A3F1313F2FE

P356

Q34286393-31C94251-B4D8-4639-94D5-3F64FFB4E353

P433

Q34286393-7844EF38-7096-44CA-B344-1109B2B14486

P478

Q34286393-BFD74E8B-409C-4720-A386-D93E670E8318

P50

Q34286393-62CCB89B-D524-46DE-8344-F44E0472984F

Q34286393-6FB35EC4-8749-46EA-B022-AA73C4FED53E

Q34286393-84A0C713-7F84-4FA1-972D-62519D89E1C7

Q34286393-855775A1-D40C-4A29-A34D-B3DC69D6146C

Q34286393-A9B56203-D8D2-4133-BF18-F667A608FCC8

Q34286393-D0D086C7-D05E-4365-9184-89A930A60954

Q34286393-E6FC97A6-B4A9-4C9A-B844-4008A2E602A7

P577

Q34286393-5A1F2E2D-DACF-4832-B27A-71537E2D5C5E

P5875

Q34286393-2AA441BA-DEA9-4723-A3A0-51039FE0B429

P698

Q34286393-DB3621DE-8C7B-4176-A266-1C3046660E7F

P921

Q34286393-B7A170A5-CB89-4015-BF76-CDA866C735A5

P932

Q34286393-3C15340C-276E-4539-96D9-061F47BF8300

P356

P1433

Annals of clinical and translational neurology

P1476

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

@en

P2093

Alzheimer's Disease Neuroimaging Initiativea

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Philip S Insel

http://www.w3.org/2001/XMLSchema#string

Susan Landau

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Brain imaging in Alzheimer disease

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

P304

534-543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACN3.81

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Michael Donohue

Michael W. Weiner

William J. Jagust

Niklas Mattsson

Henrik Zetterberg

John Q. Trojanowski

P577

2014-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264051784

http://www.w3.org/2001/XMLSchema#string

P698

25356425

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4184556

http://www.w3.org/2001/XMLSchema#string